Cancer often originates from a site of persistent inflammation, and the mechanisms turning chronic inflammation into a driving force of carcinogenesis are intensely investigated. Cyclooxygenase-2 (COX-2) is an inducible key modulator of inflammation that carries out the rate-limiting step in prostaglandin synthesis. Aberrant COX-2 expression and prostaglandin E 2 (PGE 2 ) production have been implicated in tumorigenesis. In this study we show that COX-2 is ectopically expressed in malignant T-cell lines from patients with cutaneous T-cell lymphoma (CTCL) as well as in situ in lymphocytic cells in 21 out of 22 patients suffering from mycosis fungoides (MF) in plaque or tumor stage. COX-2 is not expressed in lymphocytes of 11 patients with patch-stage MF, whereas sporadic COX-2 staining of stromal cells is observed in the majority of patients. COX-2 expression correlates with a constitutive production of PGE 2 in malignant T cells in vitro. These cells express prostaglandin receptors EP3 and EP4 and the receptor antagonist as well as small interfering RNA (siRNA) directed against COX-2, and specific COX-2 inhibitors strongly reduce their spontaneous proliferation. In conclusion, our data indicate that COX-2 mediated PGE 2 exerts an effect as a tumor growth factor in MF.
Introduction
Cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of neoplasms that primarily affect the skin. Mycosis fungoides (MF) is the most common CTCL accounting for 50% of all primary non-Hodgkin's lymphomas of the skin. 1 Chronic inflammation is a hallmark of MF that, in early stages (patch stage), resembles chronic inflammatory dermatitis. Early MF is characterized by an infiltrate of reactive inflammatory cells in the skin with rare malignant cells present in the affected areas. As the disease progresses to patch and tumor stages, the numbers of malignant cells increase. 2 The pathogenesis of MF is poorly understood; however, its typical features include an increase in the production of certain cytokines (for example, interleukin (IL)-1, IL-6, and IL-7), 3, 1 as well as an abnormal activation and function of transcription factors (for example, JunB, Stat3 and nuclear factor-kB).
2,4 MF is not curable, but early stages can be controlled over prolonged time by skin-directed therapy (for example, ultraviolet therapy, nitrogen mustard and corticosteroids). Advanced disease is treated systemically (interferon-a, rexinoids and chemotherapy) but the therapies rarely result in full remission or cure. 3 Cyclooxygenase (COX) enzymes are the rate-limiting enzymes of prostaglandin synthesis that convert arachidonic acid to the prostanoid precursor prostaglandin H 2 (PGH 2 ). COX-1 is a house-keeping gene that is constitutively expressed in many tissues. 5 The inducible COX-2, however, mediates inflammation through elevated levels of prostaglandin and has been described as one of the major players linking inflammation to cancer. 6 Its expression can be rapidly induced by agents such as IL-1, ultraviolet B, tumor necrosis factor-a or bacterial endotoxins (lipopolysaccharide). 5 The conversion of PGH 2 to prostaglandin E 2 (PGE 2 ) is carried out by one of the three prostaglandin E 2 synthases (PGES): mPGES1, PGES2 or PGES3. COX-2 works hand in hand with the inducible microsomal prostaglandin E 2 synthase 1 (mPGES1), which specifically converts COX-2 catalytic products to PGE 2 . Aberrant induction of COX-2 and mPGES1 and the subsequent production of high levels of PGE 2 have been observed in many cancers (reviewed in Samuelsson et al.
7
). PGE 2 signals are mediated through four subtypes of the E prostaglandin receptor (EP1, EP2, EP3 and EP4), each coupled to distinct G proteins. 8 A PGE 2 -induced signal and the following activation of phosphoinositide 3-kinase/Akt, protein kinase A or mitogen-activated protein kinase pathways support proliferation and survival of malignant cells, enhance their migration and invasion through the upregulation of matrix metalloproteinases and chemokine receptors and promote tumor angiogenesis through stimulation of VEGF production. 9 An involvement of COX-2 activity and PGE 2 production in carcinogenesis has been reported in solid tissue cancers such as colonic, breast and lung carcinoma, 9 as well as some hematological malignancies. 10 Recent findings suggest a role for COX-2/PGE 2 signaling in the regulation of the tumor microenvironment. 11 The inhibition of prostaglandin synthesis by a long-term use of non-steroidal antiinflammatory drugs has been shown to have a chemopreventive effect on several cancer types. 12 In this study, we provide the first evidence that PGE 2 is a COX-2-mediated growth factor in CTCL.
Materials and methods

Reagents and antibodies
7-Aminoactinomycin, anti-actin antibody and dimethylsulfoxide were from Sigma-Aldrich (Brøndby, Denmark); Celecoxib (Celebra) was from Pfizer (Ballerup, Denmark); 3-HPA (N-(3-hydroxyphenyl)5-Z, 8Z, 11Z, 14Z-eicosatetraenamide), PGE 2 and anti-EP4 antibody were from Cayman Chemical (Ann Arbor, MI, USA); PGES inhibitors MK-886 and 15d-PGJ 2 (15-deoxy-D 12,14 -prostaglandin J 2 ), EP3 (SC-51322) and EP4 antagonist (L-161 982) were from Biomol International (Exeter, UK); anti-COX-2 antibody was from BD Biosciences (San Jose, CA, USA); and anti-rabbit-fluorescein isothiocyanate and anti-mousehorseradish peroxidase antibodies were from Dako Cytomation (Glostrup, Denmark). COX-2 and non-targeting ON-TARGETplus SMARTpool small interfering RNA (siRNA) were from Dharmacon (Chicago, IL, USA).
Cell lines and cultures
MyLa1929, MyLa2000 and MyLa2059 are malignant T-cell lines established from the skin of patients with CTCL, 13, 14 and were cultured in RPMI-1640 (Sigma-Aldrich) with 10% fetal bovine serum (Life Technologies, Roskilde, Denmark), 2 mM L-glutamine and 0.1 mg/ml penicillin/streptomycin (all from Sigma-Aldrich). MyLa1929 was established from an early lesion, whereas the MyLa2000 and MyLa2059 cell lines were from advanced lesions. 13 HH 15 and Hut78 16 are malignant CTCL cell lines and were cultured under the same conditions. MySi is a non-malignant CD8 þ T-cell line from the skin, 13 and was cultured in RPMI-1640, 10% human serum (Blood Bank, State University Hospital, Copenhagen, Denmark), 2 mM L-glutamine, 0.1 mg/ml penicillin/streptomycin and 10 3 U/ml IL-2 (Proleukin, Chiron, Emeryville, CA, USA). MyLa1850 is a non-malignant CD4 þ T-cell line from the same patient as MyLa2000, 13, 14 and was cultured as MySi with 25 ng/ml IL-4 (Leinco Technologies, St Louis, MO, USA).
Patients
Patients suffering from MF in patch (n ¼ 11) or plaque/tumor (n ¼ 22) stage were included in the retrospective in situ analysis. All patients were tended by the Cutaneous Lymphoma Clinic at the Department of Dermatology, University of Wü rzburg and long-term follow-up for all patients is available. Biopsies obtained from patients with chronic dermatitis and lichen ruber served as controls. Informed consent was obtained from all patients before any of these measures.
Immunohistochemistry
The formalin-fixed, paraffin-embedded tissue sections were treated for antigen retrieval and stained with COX-2 antibody (BD Biosciences) as described previously. 17 
PGE 2 immunoassay
Analysis of PGE 2 levels in supernatants of T-cell samples was performed with the PGE 2 EIA Kit-Monoclonal (Cayman Chemical) according to the manufacturer's instructions.
RNA isolation and reverse transcriptase-PCR
Total RNA was isolated using RNeasy Mini Kit (Qiagen, Ballerup, Denmark) according to the manufacturer's instructions and reverse transcriptase-PCR was performed as described elsewhere 17 (all reagents were from Invitrogen, Paisley, UK; Taq polymerase is from New England Biolabs, Danvers, MA, USA). Primers (Supplementary Figure 1) were designed with Primer3, v 0.4.0 software (Duke-NUS Graduate Medical School, Singapore) 18 and synthesized by Eurofins MWG GmbH (Martinsried, Germany).
Protein extraction and western blotting 1À2*10 6 cells were pelleted, lysed and protein samples were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and western blotting as described previously. 17 
Flow cytometry
Cells were harvested, washed and stained as described elsewhere. 17 Samples were analyzed on a FACSCalibur using CellQuestPro software (Becton Dickinson, Brøndby, Denmark).
[methyl-
3 H]-thymidine proliferation assay
Cells were plated and pre-incubated with the relevant drugs.
Incorporation of [methyl-3 H]-thymidine (Amersham, Hillerød, Denmark; 7 mCi/sample) was determined in a microplate scintillation counter (TopCount NXT; PerkinElmer, Skovlunde, Denmark) as described in detail elsewhere. 17 
Transient transfection with siRNA
Transient transfections were performed as described previously 17 using 0.5 nmol of the respective ON-TARGETplus SMARTpool siRNA on 2*10 6 cells.
MTT assay
Samples were set up in six replicates and pre-incubated with EP antagonists in a flat-bottomed 96-well plate for 24 h. MTT buffer (5 mg/ml MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyl tetrazolium bromide) in phosphate buffered saline, sterile filtered) was added and samples were incubated for 4 h at 37 1C. MTT lysis buffer (195 g SDS, 300 ml DMF (N,N-demethylformamide), 5 ml 2.5N HCl, 23 ml 100% acetic acid and 240 ml H 2 O) was added and the plate was incubated overnight to dissolve formazan crystals. Absorbance at 562 nm was measured in a microplate reader (EL311; Bio-Tek Instruments, Inc., Brøndby, Denmark).
7-Aminoactinomycin apoptosis assay
Cells were stained with 7-aminoactinomycin, and subjected to flowcytometric analysis as described elsewhere. 19 
Results
Expression of mediators of PGE 2 synthesis and PGE 2 production in MF PGE 2 is synthesized from phospholipids of the cell membrane in a cascade whose rate-limiting step is performed by either COX-1 or COX-2. The conversion of PGH 2 into PGE 2 is carried out by one of the three PGES enzymes. We tested malignant and non-malignant CTCL lines for the expression of COX mRNA and protein by reverse transcriptase-PCR and western blotting and for the presence of PGES mRNA by reverse transcriptase-PCR (Figures 1a-c) . COX-2 mRNA was not detected in nonmalignant T-cell lines, whereas mRNA for the COX-2 enzyme was constitutively expressed in the malignant MF cell line (MyLa2000) (Figure 1a ). Western blotting showed the same results on protein level: COX-2 was detected in the malignant MF (MyLa2000, and MyLa2059; Figure 1b ) were detected in all tested malignant and COX-2 expression in mycosis fungoides KLM Kopp et al non-malignant cell lines (Figure 1c) . However, mRNA for the inducible enzyme mPGES1 was only detected in the malignant T cells. To address the functionality of these enzymes, we performed a PGE 2 enzyme immunoassay. Accordingly, malignant T cells (expressing COX-2) and non-malignant T cells (which do not express any COX enzyme) were cultivated for 24 h and supernatants assayed for PGE 2. As shown in Figure 1d , malignant T cells (MyLa2000) produced large amounts of PGE 2 (535.9, 620.8 and 1383.7 pg/ml PGE 2 produced by a number of 0.25*10 6 , 0.5*10 6 and 1*10 6 cells, respectively), whereas PGE 2 was barely detectable in supernatants from cultures of nonmalignant T cells (MyLa1850).
COX-2 expression in MF patients in situ
To address whether COX-2 is also expressed in malignant T cells in vivo, we examined COX-2 expression in specimens from 33 MF patients in patch (n ¼ 11) or plaque/tumor stage (n ¼ 22) (Figure 2) . Notably, all samples were obtained during the process of confirming the clinical diagnosis of MF before initiation of a specific therapy and none of the patients suffered from a clinically apparent infection. lower panels show a typical example from a lichen ruber patient (Figures 2m-p) . In samples obtained from tumor-stage MF, all lymphocytes, including those judged as malignant by morphology (for example, irregular nuclei), localization (for example, epidermotropic) or immunohistochemistry phenotype in serial sections (for example, CD4 þ and CD7À), stained COX-2 positive (Figures 2a-d) . A high frequency of COX-2-positive lymphocytes was also observed in plaque lesions (Figures 2e-h) , and, in general, positive staining for COX-2 was observed in lymphocytic cells in 21 of 22 samples obtained from patients with advanced disease, that is, plaque or tumor. In contrast, lymphocytic cells did not show COX-2 expression in samples obtained from patients with patch-stage MF, whereas stroma cells with dendritic or spindle phenotype (such as macrophages) sporadically expressed COX-2 in these lesions (Figures 2i-l) . COX-2 expression was not observed in lymphocytic cells in lesions from patients with lichen ruber or chronic delayed-type hypersensitivity dermatitis (Figures 2m-p , and data not shown).
PGE 2 signaling in malignant T cells
PGE 2 signals are transmitted through G-protein-coupled EP receptors. To evaluate a possible role of PGE 2 signals in malignant MF T-cell growth, we incubated MyLa2000 cells in fresh medium with up to 20 mM exogenous PGE 2 . After 24 h of culture, cell proliferation was increased in a dose-dependent manner up to 40% (Figure 3a) , suggesting that malignant T cells express functional EP receptors. It is known that PGE 2 induces COX-2 expression in a positive feedback loop through the EP4 receptor. 20 When MyLa2000 cells were incubated with exogenous PGE 2 , COX-2 protein expression was enhanced in a dose-dependent way compared with the control (Figure 3b ), indicating that a similar feedback loop involving EP4 is operating in malignant T cells. Indeed, malignant T cells expressed the EP4 receptor as judged from mRNA ( Figure 3c ) and surface expression in flow cytometry (Figure 3d ). In addition, malignant cells expressed the EP3 receptor, whereas the EP1 and EP2 receptors were not expressed (Figure 3c ). To evaluate the relevance of an autocrine EP3-or EP4-mediated PGE 2 signal in malignant T cells, MyLa2000 cells were cultured with selective EP3 (SC-51322) or EP4 (L-161 982) antagonists and viability was measured. As shown in Figure 3e , the mitochondrial activity was decreased by 50 and 70%, respectively, whereas incubation with corresponding amounts of dimethylsulfoxide had no effect. Taken together, these data suggest that PGE 2 delivers growth and/or survival signals through EP3 and EP4 receptors in malignant MF T cells. As mentioned above, early-stage MF (MyLa1929) and non-malignant T cells (MyLa1850 and MySi) do not produce PGE 2. Yet, they express PGE 2 receptors (Figure 3 , and data not shown) and show an enhanced proliferation when cultured in the presence of exogenous PGE 2 (Supplementary Figure 3) .
Inhibition of PGE 2 synthesis in malignant MF T cells
Inhibition of COX-2 has been shown to have antiproliferative and apoptosis-inducing effects on different cancer cell lines. 21, 22 To further examine whether PGE 2 signals have an autocrine function, malignant T cells (MyLa2000) were transfected with siRNA against COX-2 and spontaneous proliferation was determined by Figure 2b) , whereas nonmalignant T cells (MySi and MyLa1850) were largely unaffected by concentrations up to 10 mg/ml. PGES inhibitors, which block PGE 2 synthesis downstream of COX-2, strongly inhibited the spontaneous proliferation of malignant T cells ( Figure 4c) ; proliferation was impeded almost completely at 15d-PGJ 2 concentrations below 10 mM.
Celecoxib is a selective COX-2 inhibitor for treatment of rheumatoid arthritis. 23 To examine its potential value in the therapy of MF, we treated malignant and non-malignant T-cell cultures with celecoxib and determined cell proliferation (Figure 4d ). The data show that whereas non-malignant T cells were hardly affected by celecoxib concentrations up to 100 mM, proliferation of malignant cells was reduced by up to 40% at 50 mM and almost completely inhibited at a concentration of 100 mM. Some groups reported on COX-2-independent effects of celecoxib at administration of high concentrations generally used in vitro studies. 24 Accordingly, we treated MyLa2000 cells with celecoxib and increasing concentrations of exogenous PGE 2 to analyze whether the observed antiproliferative effect was actually PGE 2 dependent. As expected, celecoxib at a concentration of 50 mM (Figure 4e , left) or 75 mM (Figure 4e , right) inhibited the spontaneous proliferation by 40 and 60%, respectively. However, the inhibitory effects were reversed by simultaneous administration of PGE 2 in a dose-dependent way at concentrations above 20 mM (Figure 4e ). In contrast, it was not 
COX-2 expression in mycosis fungoides
KLM Kopp et al possible to fully restore proliferation in cultures that were treated with 100 mM celecoxib (data not shown), indicating that celecoxib at concentrations this high could have additional PGE 2 -independent, antiproliferative effects. To further characterize the observed effect of celecoxib on malignant T cells, we performed an apoptosis assay on celecoxib-treated MyLa2000 cells. The percentage of apoptotic cells was determined in samples treated for 24 and 48 h and compared with the inhibition of 3 H-thymidine uptake (Supplementary Figure 4) . After 24 h of culture, celecoxib induced 450% reduction of proliferation, whereas only a marginal increase in apoptosis was observed (Supplementary Figure 4a) . A similar but more pronounced picture was observed after 48 h of culture (Supplementary Figure 4b) . This suggests that COX-2 inhibition primarily triggers growth arrest rather than apoptosis in malignant T cells.
Discussion
In this study we provide the first evidence of an ectopic COX-2 expression and its possible pathogenic role in MF. Thus, malignant T cells isolated from skin specimens of patients with MF showed COX-2 expression, whereas non-malignant T cells did not. Moreover, lymphocytes with a malignant phenotype also showed COX-2 expression in situ in plaque or tumor stage, indicating that malignant T cells express COX-2 in vivo in a large fraction of patients with advanced MF. Aberrant COX-2 was recently implicated in malignant transformation in solid tissue cancers such as colon, breast and lung cancer. 9 The present findings that the ectopic expression of COX-2 is most pronounced in tumor-stage MF suggest that COX-2 may also have a role in malignant transformation in MF.
COX-2 and mPGES1 are the key players involved in PGE 2 synthesis and have attracted special attention because PGE 2 is the principal prostaglandin produced in cancer and believed to promote malignant cell growth, angiogenesis and metastasis. 9 In this study we show that malignant T cells spontaneously produce PGE 2 , whereas COX-2-negative, non-malignant T cells do not. Our observation that inhibition of COX-2 activity by siRNA as well as specific inhibitors strongly reduced proliferation of malignant T cells in vitro and the fact that this inhibition was overridden by exogenous PGE 2, support the notion that COX-2-dependent PGE 2 is involved in the regulation of proliferation of malignant MF T cells. This conclusion is in keeping with findings that aberrant COX-2 expression has a regulatory role in proliferation and apoptosis in other malignancies. The compound 3-HPA seems to be slightly more potent than celecoxib, and celecoxib has been described to have COX-2-independent side effects; however, celecoxib is already an approved anti-inflammatory drug (whereas 3-HPA is not). For this reason, we judged it of high importance to put emphasis on celecoxib in relation to its therapeutic potential in MF.
mPGES1 has emerged as a novel therapeutic target in various diseases. 7 We give evidence for its expression in malignant T cells and show that inhibitors of PGES strongly suppress proliferation of these cells. Moreover, the malignant T cells express EP3 and EP4 receptors, respond to exogenous PGE 2 and are inhibited by EP3 and EP4 antagonists.
Taken together, these data suggest that COX-2-dependent PGE 2 is a growth factor enhancing proliferation of malignant CTCL T cells in advanced MF. Our observations that PGE 2 also enhanced growth of COX-2-negative early-stage MF and nonmalignant T cells (that do express a set of EP receptors) suggest a paracrine function of PGE 2 . Given the COX-2 expression in stromal cells of patch-stage patients, we therefore hypothesize that COX-2 may also contribute to chronic inflammation and disease progression in the early stages of MF.
As PGE 2 may deliver antiapoptotic signals, it was important to ask whether the growth inhibition by COX-2 inhibitors was caused by induction of apoptosis, as previously described in colon cancer cell lines. 25 To our surprise, inhibition of PGE 2 synthesis for 24 and 48 h triggered only a weak induction of apoptosis in the malignant T cells compared with the profound inhibition of 3 H-thymidine uptake. Thus, COX-2 inhibition primarily triggers growth arrest rather than apoptosis in malignant CTCL T cells. As an aberrantly high nuclear factor-kB activity protects malignant CTCL T cells from apoptosis, 4 it may be speculated that the combination of COX-2 inhibitors and inducers of apoptosis, such as nuclear factor-kB inhibitors, exert an effect synergistically in the inhibition of malignant T cells. It is worth stressing that an advanced CTCL is very difficult to treat, the existing systemic therapies have severe side effects, many patients experience refractory disease and no definitive curative therapy exists today. 26 It is agreed upon that the development of new treatments is of uttermost importance. In this light, it is highly relevant that celecoxib inhibited growth of malignant T cells in vitro. COX-2 inhibitors are already in use for treatment of pain and rheumatoid arthritis. As these drugs are generally well tolerated, they have become attractive candidates as new less-toxic adjuvant therapy of cancer. Indeed, the perspective of a combinatorial therapy with COX-2 inhibitors and antineoplastic drugs is raising hopes for novel possibilities in cancer treatment. 27 In conclusion, we provide the first evidence that COX-2 is expressed in MF, and that PGE 2 is a COX-2-dependent growth factor for malignant T cells. We propose that COX-2 and downstream players in PGE 2 synthesis are novel therapeutic targets in MF.
